Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NVO

Novo Nordisk ADR

May 07 • 04:00PM ET

45.80

+0.04 0.09 %

Healthcare • Drug Manufacturers - General • Denmark • Large • NYSE

May 06, 7:50 AMNovo Nordisk beats Q1 estimates as Wegovy revenue doubles forecasts and 2026 sales, profit decline guidance narrows to 4%-12%

Peers: LLY SNY MRK AZN NVS PFE JNJ GSK BMY ABBV

| Held by: PVAL PPH AVDE PID WCMI PINK AQEC APIE OZEM NVOH

Scroll to Statements

Index	-	P/E	10.75	EPS (ttm)	4.26	Insider Own	0.00%	Shs Outstand	3.36B	Perf Week	8.48%
Market Cap	154.31B	Forward P/E	13.79	EPS next Y	3.32	Insider Trans	-	Shs Float	3.36B	Perf Month	21.78%
Enterprise Value	173.54B	PEG	689.58	EPS next Q	0.82	Inst Own	9.29%	Short Float	0.51%	Perf Quarter	5.68%
Income	18.95B	P/S	3.03	EPS this Y	-9.15%	Inst Trans	-0.36%	Short Ratio	0.83	Perf Half Y	-5.08%
Sales	50.91B	P/B	6.48	EPS next Y	0.46%	ROA	24.14%	Short Interest	17.02M	Perf YTD	-9.98%
Book/sh	7.06	P/C	46.27	EPS next 5Y	0.02%	ROE	73.79%	52W High	81.44 -43.76%	Perf Year	-32.20%
Cash/sh	0.99	P/FCF	24.05	EPS past 3/5Y	26.28% 20.36%	ROIC	38.15%	52W Low	35.12 30.41%	Perf 3Y	-43.89%
Dividend Est.	1.79 (3.90%)	EV/EBITDA	6.55	Sales past 3/5Y	23.19% 19.21%	Gross Margin	81.84%	Volatility	2.65% 2.60%	Perf 5Y	21.07%
Dividend TTM	1.80 (3.93%)	EV/Sales	3.41	EPS Y/Y TTM	26.26%	Oper. Margin	45.45%	ATR (14)	1.40	Perf 10Y	71.70%
Dividend Ex-Date	Mar 30, 2026	Quick Ratio	0.56	Sales Y/Y TTM	16.79%	Profit Margin	37.23%	RSI (14)	73.45	Recom	2.54
Dividend Gr. 3/5Y	26.98% 19.93%	Current Ratio	0.79	EPS Q/Q	86.54%	SMA20	10.98%	Beta	0.79	Target Price	48.65
Payout	36.87%	Debt/Eq	0.72	Sales Q/Q	37.63%	SMA50	17.50%	Rel Volume	0.81	Prev Close	45.76
Employees	68794	LT Debt/Eq	0.59	Earnings	May 06 BMO	SMA200	-7.80%	Avg Volume	20.44M	Price	45.80
IPO	Apr 30, 1981	Option/Short	Yes / Yes	EPS/Sales Surpr.	18.04% 1.50%	Trades		Volume	16,912,604	Change	0.09%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-26	Initiated	Wolfe Research	Peer Perform
Mar-18-26	Initiated	Bernstein	Underperform
Mar-18-26	Initiated	Bernstein	Outperform	$175
Mar-10-26	Downgrade	TD Cowen	Buy → Hold	$42
Mar-03-26	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$40
Mar-02-26	Downgrade	Goldman	Buy → Neutral	$41
Feb-24-26	Downgrade	Kepler	Buy → Hold
Feb-24-26	Downgrade	JP Morgan	Overweight → Neutral
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-12-26	Upgrade	Jefferies	Underperform → Hold
Jan-27-26	Initiated	Citigroup	Neutral
Dec-08-25	Downgrade	Argus	Buy → Hold
Oct-27-25	Resumed	Jefferies	Underperform
Oct-01-25	Upgrade	HSBC Securities	Hold → Buy
Sep-29-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$47
Sep-17-25	Upgrade	Berenberg	Hold → Buy
Sep-16-25	Upgrade	Rothschild & Co Redburn	Neutral → Buy
Sep-09-25	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-13-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$54
Aug-05-25	Downgrade	UBS	Buy → Neutral

Show Previous Ratings

Today 07:34AM	Novos CEO champions record-breaking start for Wegovy pill in US market (Pharmaceutical Technology)
May-07-26 02:39PM	Novo Nordisk Surges 9.2% As Wegovy Pill Fuels Momentum (GuruFocus.com)
02:29PM	Amazon Adds Same-Day Ozempic Pill Delivery (GuruFocus.com)
02:05PM	Amazon Expands GLP 1 Push With Ozempic Pill (GuruFocus.com)
08:46AM	Amazon adds Ozempic pill to pharmacy kiosks with same-day delivery (Quartz)
12:01AM	Loading…
12:01AM	Scoring 2 Million Prescriptions, Novos GLP-1 Pill Crushes Expectations (The Daily Upside)
May-06-26 03:05PM	Novo Nordisk CEO: Open to deals, we need the broadest pipeline in the world (CNBC TV)
11:06AM	Novo Nordisk surges as Wegovy pill demand crushes estimates (Yahoo Finance Video)
10:54AM	Novo Nordisk Swallows the Competition with Wegovy Pill Surge (Moby)
10:53AM	Novo Nordisk posts mixed quarter despite strong demand (GuruFocus.com)
10:52AM	Novo Nordisk beats estimates, raises guidance on Wegovy pill surge (Proactive)
10:04AM	Sales of Novo Nordisk's New Weight-Loss Pill Are Off To a Strong Start. The Stock Is Rising (Investopedia)
09:15AM	Novo Nordisk Raises Outlook as GLP-1 Demand Stays Strong (GuruFocus.com)
08:15AM	5 Things to Know Before the Stock Market Opens (Investopedia)
07:40AM	Novo Nordisk Q1 2026 earnings beat on Wegovy pill demand (Quartz)
07:40AM	Loading…
07:40AM	Novo Nordisk beats estimates and shares surge on demand for weight loss pill (Quartz)
06:35AM	Novo Nordisk (NVO) lifts 2026 outlook as obesity drug demand remains strong (InvestorsHub)
06:12AM	Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. (Barrons.com)
05:27AM	Walt Disney headlines earnings slate (MarketWatch)
03:25AM	Novo Nordisk says the Wegovy pill saw the fastest take-up in weight-loss drug history. (MarketWatch)
03:23AM	European shares advance on Mideast peace deal optimism; earnings on watch (Reuters)
01:41AM	Novo Nordisk: Q1 Earnings Snapshot (Associated Press)
May-05-26 07:49AM	Novo Nordisk Faces Price War as Weight-Loss Pill Demand Rises (GuruFocus.com)
06:27AM	Novo Nordisks Weight-Loss Pill Momentum Faces Pricing Pressure (InvestorsHub)
May-04-26 09:48AM	FDA Reports Liver Failure in Patient Taking Lilly's Foundayo (Barrons.com)
09:04AM	Why Eli Lilly stock is down 3% today: FDA adverse event data explained (Investing.com)
06:00AM	Earnings live updates: Palantir posts record Q1 revenue, Pinterest stock soars on ad-boosting AI tools, Tyson's high-protein bet pays off (Yahoo Finance)
05:46AM	Novo Nordisk to launch Ozempic for type 2 diabetes in US (Pharmaceutical Business Review)
May-01-26 03:50PM	Novo Nordisk Launches Ozempic Pill in U.S. (GuruFocus.com)
11:40AM	Novo Launches Ozempic Pills Across 70,000 US Pharmacies (GuruFocus.com)
11:39AM	Loading…
11:39AM	Novo Nordisk rolls out Ozempic pill in the U.S. (GuruFocus.com)
10:50AM	Eli Lilly Stocks Path To 30% Upside (Trefis)
09:57AM	Can GLP-1s curb alcohol use? A new study says the drugs can reduce heavy drinking. (MarketWatch)
06:45AM	Novo Nordisk CEO on Wegovy pills U.S. future as Iran war threatens supply chains (CNN Business)
Apr-30-26 05:47PM	US prescription spending could top $1 trillion. GLP-1s lead the way (USA TODAY)
04:31PM	FDA proposes curbs on mass copycats of Novo, Lilly's weight-loss drugs (USA TODAY)
03:04PM	Eli Lilly Rises on FDA Compounding Proposal (GuruFocus.com)
03:04PM	Avalyn Pharma Surges 44% After $300 Million Upsized IPO (GuruFocus.com)
03:03PM	Eli Lilly, Novo Stocks Jump as FDA Moves to Limit Compounded GLP-1 Drugs (GuruFocus.com)
02:23PM	Squawk Pod: Just so grateful. Artemis II crew & Eli Lilly's new GLP-1 pill - 04/30/26 Audio Only (CNBC TV)
11:06AM	Qualcomm stock surges on data center demand, Eli Lilly lifts outlook (Yahoo Finance Video)
06:58AM	Lilly's stock rallies as sales of GLP-1 drugs nearly double (MarketWatch)
Apr-29-26 03:19PM	Eli Lilly Slips as Canada Approves Generic Weight-Loss Drug (GuruFocus.com)
03:11PM	Meta is heading into earnings with a big move expected (GuruFocus.com)
Apr-28-26 12:29PM	Erasca Stock Sinks 50% in Race for 'Miracle' Cancer Drug. What's Behind the Historic Sell-Off. (Barrons.com)
07:44AM	Boehringer dual-acting obesity shot hits mark in Phase 3 trial (BioPharma Dive)
Apr-27-26 10:02AM	GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival (Proactive)
09:48AM	As Investors Focus on Lilly's Foundayo, They May Be Overlooking Another Key Catalyst (Barrons.com)
Apr-24-26 01:53PM	Eli Lilly Stock Falls. Novo Extends Lead in Weight-Loss Drug Race (GuruFocus.com) +6.88%
01:12PM	Eli Lilly Slips as Obesity Prescriptions Lag (GuruFocus.com)
11:46AM	Eli Lilly Stock Falls. Foundayo Is Fighting to Catch Novo's Wegovy Pill. (Barrons.com)
11:00AM	Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims (Yahoo Finance Video)
09:44AM	Intel upgraded, DraftKings downgraded: Wall Street's top analyst calls (The Fly)
06:46AM	Lilly tumbles on Foundayos shaky week; FDA to issue vouchers for psychedelics (BioPharma Dive)
Apr-23-26 02:41PM	Hims Stock Falls as It Pivots From GLP-1 Compounding. Why the 'Netflix' Argument Is Failing. (Barrons.com)
12:47PM	This Pharma Stock Is Soaring After Earnings. It's a Sneaky GLP-1 Play. (Barrons.com)
11:53AM	Hims Stock Drops on LillyDirect Deal. Can It Be the Netflix of Pharma? (Barrons.com)
11:01AM	Novo Nordisk Advances Ozempic Pill for Kids (GuruFocus.com)
10:44AM	Hims Yields Ground in GLP-1 Market. Why Its CEO Is Calling It the Netflix of Pharma. (Barrons.com)
10:06AM	Hims & Hers jumps 7% after expanding partnership with Eli Lilly (InvestorsHub)
Apr-21-26 04:25PM	Amazon launching weight loss drug program via One Medical (Quartz)
01:54PM	Health insurers raise questions about Medicare program that will offer GLP-1s to seniors for $50 (MarketWatch)
01:30PM	Lilly and Novo Stocks Are Tumbling. How Amazon Is Shaking Up the GLP-1 Game. (Barrons.com)
Apr-20-26 10:47AM	Novo's Once-Daily Sickle Cell Pill Hits Milestone. A Smaller Rival Is Sinking 24%. (Barrons.com)
10:33AM	Beyond GLP-1Rs: emerging targets poised to gain share of obesity market (Pharmaceutical Technology)
10:16AM	Agios Pharmaceuticals stock tumbles 25% after Novo data (Investing.com)
Apr-17-26 10:02AM	Eli Lilly Weight-Loss Pill Prescriptions Near 1,400 in First Week (GuruFocus.com)
06:04AM	Lillys obesity pill off to a strong start; OpenAI debuts new drug discovery tool (BioPharma Dive)
Apr-16-26 04:38PM	Kailera nets $625M in one of biotechs biggest-ever IPOs (BioPharma Dive)
03:57PM	Novo Workforce Changes May Signal Ongoing Reset (GuruFocus.com)
01:13PM	Novo Nordisk Expands Workforce After Deep Cuts (GuruFocus.com)
10:45AM	Hims & Hers stock extends gains as RFK Jr. signals FDA will consider looser restrictions on peptides (Yahoo Finance)
10:45AM	Hims & Hers stock extends gains as FDA considers looser restrictions on peptides (Yahoo Finance)
Apr-15-26 04:05PM	Lilly Stock Dips on FDA Request for More Foundayo Safety Data. Is the Market Reaction Overblown? (Barrons.com)
06:56AM	Novo Resources appoints GM of exploration ahead of Wyloo drilling (Proactive)
05:39AM	FDA asks Lilly to evaluate obesity pills liver risk (BioPharma Dive)
Apr-14-26 08:12PM	Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval? (Quartz)
03:14PM	Novo Nordisk CEO: This is where science meets speed and scale (CNBC TV)
11:56AM	Novo Bets on OpenAI to Rebuild Its Obesity Edge (GuruFocus.com)
11:54AM	Wall Street Resets Novo Nordisk Price Target (GuruFocus.com)
11:52AM	Novo Nordisk Is Bringing AI Into The Core Of Its Business (GuruFocus.com)
09:11AM	Novo Nordisk's stock rallies after drugmaker reveals deal with OpenAI (MarketWatch)
08:58AM	Novo Nordisk Taps OpenAI to Accelerate Drug Development (GuruFocus.com)
07:27AM	Novo Nordisk Stock Rises. An OpenAI Partnership Can Help It Find the Next Ozempic. (Barrons.com)
07:24AM	Novo Nordisk partners with OpenAI to speed weight loss drug discovery (Quartz)
07:00AM	Novo Nordisk and OpenAI forge alliance to drive speedy drug development (Pharmaceutical Technology)
06:05AM	These Stocks Are Today's Movers: Intel, American, Oracle, Novo Nordisk, Bloom Energy, Globalstar, JPMorgan, and More (Barrons.com)
04:30AM	GLP-1 giant Novo Nordisk partners with OpenAI as pharma industry's AI race accelerates (Proactive)
02:04AM	Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development (Reuters)
Apr-13-26 11:43AM	How Eli Lilly Stock Rises To $2,000 (Trefis)
Apr-11-26 06:00AM	Wyloo project drilling to drive Novo news flow - ICYMI (Proactive)
Apr-10-26 12:08PM	Novo Nordisk's GLP-1 pill momentum faces pricing test, says leading bank (Proactive)
09:26AM	Why Is HIMS Stock Down 40%? (Trefis)
09:03AM	Eli Lilly loses weight loss drug market share as generics flood India (Quartz)
Apr-09-26 03:30PM	Novo Nordisk's weight loss pill is drawing in new patients for obesity treatment (CNBC TV)
01:27PM	Eli Lilly's Foundayo Weight-Loss Pill Hits the Shelves. It's a Turning Point for the Stock. (Barrons.com)
01:25PM	CRWV, CVX, LLY, TSLA Lead Thursday Watchlist (GuruFocus.com)
01:23PM	Eli Lilly Stock in Focus -- New Pill Launch Challenges Novo Nordisk (GuruFocus.com)
01:20PM	Amazon Push Into GLP-1 Access Expands Healthcare Reach (GuruFocus.com)
11:14AM	Semaglutide Generics Drive 33% Share As India GLP-1 Market Shifts (GuruFocus.com)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Nordisk A/S	10% Owner	May 30 '25	Proposed Sale	2.14	921,897	1,972,859		May 30 08:31 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVO

Novo Nordisk ADR

Upgrade your Finviz experience